Clinical trials for bispecific antibodies in multiple myeloma
| Agent . | Targets . | Phase . | Clinical trial number . | Status . |
|---|---|---|---|---|
| AMG420 | BCMAxCD3 | 1 | NCT03836053 | Completed |
| AMG701 | BCMAxCD3 | 1/2 | NCT03287908 | Ongoing |
| CC-93269 | BCMAxCD3 | 1 | NCT03486067 | Ongoing |
| PF-06863135 | BCMAxCD3 | 1 | NCT03269136 | Ongoing |
| REGN5458 | BCMAxCD3 | 1/2 | NCT03761108 | Ongoing |
| JNJ-64007957 | BCMAxCD3 | 1b1 | NCT04108195NCT03145181 | OngoingOngoing |
| TNB-383B | BCMAxCD3 | 1 | NCT03933735 | Ongoing |
| GBR1342 | CD38xCD3 | 1/2 | NCT03309111 | Ongoing |
| AMG424 | CD38xCD3 | 1 | NCT03445663 | Ongoing |
| JNJ-64407564 | GPRC5dxCD3 | 1b1 | NCT04108195NCT03399799 | OngoingOngoing |
| BFCR4350A | FCRH5xCD3 | 1 | NCT03275103 | Ongoing |
| Agent . | Targets . | Phase . | Clinical trial number . | Status . |
|---|---|---|---|---|
| AMG420 | BCMAxCD3 | 1 | NCT03836053 | Completed |
| AMG701 | BCMAxCD3 | 1/2 | NCT03287908 | Ongoing |
| CC-93269 | BCMAxCD3 | 1 | NCT03486067 | Ongoing |
| PF-06863135 | BCMAxCD3 | 1 | NCT03269136 | Ongoing |
| REGN5458 | BCMAxCD3 | 1/2 | NCT03761108 | Ongoing |
| JNJ-64007957 | BCMAxCD3 | 1b1 | NCT04108195NCT03145181 | OngoingOngoing |
| TNB-383B | BCMAxCD3 | 1 | NCT03933735 | Ongoing |
| GBR1342 | CD38xCD3 | 1/2 | NCT03309111 | Ongoing |
| AMG424 | CD38xCD3 | 1 | NCT03445663 | Ongoing |
| JNJ-64407564 | GPRC5dxCD3 | 1b1 | NCT04108195NCT03399799 | OngoingOngoing |
| BFCR4350A | FCRH5xCD3 | 1 | NCT03275103 | Ongoing |